Abstracts tagged "pain and rheumatoid arthritis (RA)"

Abstract Number: 1880 • 2019 ACR/ARP Annual Meeting
Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials
Janet Pope¹, Yvonne Lee ², Jeffrey Curtis ³, Daojun Mo ⁴, Terence Rooney ⁴, Li Xie ⁴, Christina Dickson ⁴, Douglas Schlichting ⁴, Amanda Quebe ⁴, Anabela Cardoso ⁴, Lee Simon ⁵ and Peter Taylor ⁶, ¹Western University, London, ON, Canada, ²Northwestern University Feinberg School of Medicine, Chicago, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵SDG LLC, Cambridge, MA, ⁶University of Oxford, Oxford, United Kingdom
Background/Purpose: Opioid use in RA patients has increased over the past 2 decades in the US. Little is known about the combined effects of opioids…
Abstract Number: 240 • 2018 ACR/ARHP Annual Meeting
Bi-Directional Associations between “Too Much Sitting” and Self-Reported Pain in Patients with Rheumatoid Arthritis
Ciara O'Brien¹, Joan L. Duda¹, Jet J.C.S. Veldhuijzen van Zanten^1,2, George S. Metsios^2,3, George D. Kitas^1,2,4 and Sally A.M. Fenton^1,2, ¹School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, United Kingdom, ²Department of Rheumatology, Russells Hall Hospital, Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom, ³Faculty of Education Health & Wellbeing, University of Wolverhampton, Walsall, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom
Background/Purpose: Epidemiological evidence indicates that sedentary behaviour, or “too much sitting”, is associated with poor health outcomes in the general population, including elevated systemic inflammation.…
Abstract Number: 452 • 2018 ACR/ARHP Annual Meeting
Features of Peripheral and Central Sensitization and Neuropathic Pain Are Seen in Both Osteoarthritis and Rheumatoid Arthritis
Jacquelin R. Chua¹, Shingo Ishihara², Mariam Riad¹, Isabel Castrejón¹, Rachel E. Miller³, Anne-Marie Malfait⁴, Joel A. Block¹, Theodore Pincus¹ and Najia Shakoor¹, ¹Division of Rheumatology, Rush University Medical Center, Chicago, IL, ²Internal Medicine, Rush University Medical Center, Chicago, IL, ³Biochemistry, Rush University Medical Center, Chicago, IL, ⁴Biochemistry & Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: OA and RA are among the most common chronic painful rheumatic diseases. Appreciation of the role of pain sensitization in OA has revolutionized the…
Abstract Number: 599 • 2018 ACR/ARHP Annual Meeting
Comparative Effectiveness in Pain and HAQ-DI Improvement for Baricitinib Versus Adalimumab, Tocilizumab, and Tofacitinib Monotherapies in Csdmard-Naïve Rheumatoid Arthritis Patients: A Matching-Adjusted Indirect Comparison (MAIC)
Bruno Fautrel¹, Baojin Zhu², Peter C. Taylor³, Mart van de Laar⁴, Paul Emery⁵, Francesco de Leonardis², Carol L. Gaich², Claudia Nicolay², Zbigniew Kadziola², Inmaculada de la Torre⁶ and Roy Fleischmann⁷, ¹University Pierre et Marie Curie, Paris, France, ²Eli Lilly and Company, Indianapolis, IN, ³Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ⁴Arthritis Centre Twente, University of Twente, Enschede, Netherlands, ⁵Leeds MSK Biomed/Chapel Allerton Hospital, Leeds, United Kingdom, ⁶Eli Lilly and Company, Madrid, Spain, ⁷Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: In Phase 3 trial (RA-BEGIN), baricitinib (BARI) monotherapy demonstrated superiority to MTX in pain reduction and HAQ-DI improvement in treatment of csDMARD-naïve active RA…
Abstract Number: 1068 • 2018 ACR/ARHP Annual Meeting
Characterization of the Role of Endocannabinoid System Using Jwh-133, a Selective Cannabinoid CB2 Receptor Agonist, in IL-1β-Induced Inflammation in Human Rheumatoid Arthritis Synovial Fibroblasts
Sabrina Fechtner¹, Anil K. Singh¹ and Salahuddin Ahmed^1,2, ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ²Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA
Background/Purpose: The endocannabinoid system (ECS) is comprised of two evolutionary conserved cannabinoid receptors 1 and 2 (CB1 and CB2) which participate in pain management through…
Abstract Number: 2472 • 2018 ACR/ARHP Annual Meeting
The Impact of Disease Activity and Patient Reported Outcomes on Grip Force over Time in Early Rheumatoid Arthritis
Maria Rydholm^1,2, Ingegerd Wikström^1,2, Sofia Hagel³, Lennart Jacobsson⁴ and Carl Turesson^1,2, ¹Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Although patients with early rheumatoid arthritis (RA) have substantially reduced grip strength compared to the general population, some improvement over time has been demonstrated…
Abstract Number: 2475 • 2018 ACR/ARHP Annual Meeting
Promis Pain Interference 6b and Fatigue 7a Short Forms and Profile-29 in Rheumatoid Arthritis Patients Treated with TNF Inhibitors
Clifton O. Bingham III¹, Sergio Schwartzman², Shelly Kafka³, Dennis Parenti³, Shawn Black³, Stephen Xu⁴, Wayne Langholff⁴ and Jeffrey R. Curtis⁵, ¹Johns Hopkins University, Baltimore, PA, ²Weill Cornell Medical College, New York, NY, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: PROMIS (Patient Reported Outcomes Measurement Information System) has been used in rheumatoid arthritis (RA) patients (Pts) to assess disease activity across multiple domains (i.e.…
Abstract Number: 2219 • 2017 ACR/ARHP Annual Meeting
Remaining Pain in DMARD-Naive Rheumatoid Arthritis Patients Treated with Baricitinib and Methotrexate
Yvonne C. Lee¹, Paul Emery², John D. Bradley³, Baojin Zhu³, Carol L Gaich³, Zhihong Cai⁴, Amanda Quebe³, Anabela Cardoso³, Yun-Fei Chen³ and Roy Fleischmann⁵, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Leeds Musculoskeletal Biomedical Research Unit, LTHT Leeds Institute of Rheumatic and Musculoskeletal Medicine University of Leeds, Leeds, United Kingdom, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly Japan K.K., Kobe, Japan, ⁵University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Patient (pt)-reported pain is common in rheumatoid arthritis (RA), even in pts with good disease control1. This analysis evaluated pain control achieved by methotrexate…
Abstract Number: 2238 • 2017 ACR/ARHP Annual Meeting
Mapping Paindetect, a Neuropathic Pain Screening Tool, to Patient-Reported Outcomes Measurement Information System (PROMIS) 29 in Patients with Rheumatoid Arthritis: Developing a Neuropathic Pain Scale As a Measure of Treatment Outcome
Yong Gil Hwang¹, Lei Zhu², Ajay Wasan³ and Larry W. Moreland¹, ¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Departments of Anesthesiology and Psychiatry, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: To investigate relationships between painDETECT (PDQ), neuropathic pain screening tool, and patient-reported outcomes measurement information system (PROMIS) 29 in patients with rheumatoid arthritis…
Abstract Number: 338 • 2017 ACR/ARHP Annual Meeting
Measurement Properties of Paindetect, a Neuropathic Pain Screening Tool, for Evaluating Pain Phenotype in Patients with Rheumatoid Arthritis: Developing Neuropathic Pain Scale As a Measure of Treatment Outcome By Applying Rasch Analysis
Yong Gil Hwang¹, Lei Zhu², Ajay Wasan³ and Larry W. Moreland¹, ¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³Departments of Anesthesiology and Psychiatry, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Ongoing pain state in rheumatoid arthritis (RA) often persists after the resolution of inflammation, indicating the transition between the acute inflammatory pain and post-inflammatory…
Abstract Number: 423 • 2017 ACR/ARHP Annual Meeting
Refractory Pain in Spite of Inflammation Control after Start of Anti-TNF Therapy in RA: Observational Data from Southern Sweden
Tor Olofsson¹, Johan K Wallman², Maria EC Schelin³, Anna Jöud⁴ and Jon Lampa⁵, ¹Lund University, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, Lund, Sweden, ²Department of Clincial Sciences Lund, Rheumatology, Lund University, Lund, Sweden, ³Lund University, Department of Clinical Sciences Lund, Oncology, Lund, Sweden, Lund, Sweden, ⁴Lund University, Department of Laboratory Medicine Lund, Division of Occupational and Environmental Medicine, Lund, Sweden, Lund, Sweden, ⁵Karolinska Institute, Department of Medicine, Rheumatology Unit, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Pain is a dominant and debilitating feature of RA, but while a lot of focus has been put on the occurrence and management of…
Abstract Number: 499 • 2017 ACR/ARHP Annual Meeting
Assessment of Early Improvement in Pain and Other ACR Components As Predictors for Achieving Low Disease Activity or Remission in Three Phase 3 Trials of RA Patients Treated with Baricitinib
Michael Weinblatt¹, Mark C. Genovese², Joel Kremer³, Luna Sun⁴, Himanshu Patel⁴, Alisa Koch⁴, David Muram⁴, Jeffrey R. Curtis⁵, Cynthia J. Larmore⁴ and Baojin Zhu⁴, ¹Brigham and Women’s Hospital, Boston, MA, ²Stanford University Medical Center, Palo Alto, CA, ³The Center for Rheumatology, Albany Medical College, Albany, NY, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The purpose of this analysis was to assess whether early improvement in ACR components could act as predictors of low disease activity (LDA)…
Abstract Number: 855 • 2017 ACR/ARHP Annual Meeting
Rapid and Sustained Pain Improvement in Rheumatoid Arthritis Patients Treated with Baricitinib Compared to Adalimumab or Placebo
Peter C. Taylor¹, Roy Fleischmann², Elizabeth Perkins³, Jeffrey Lisse⁴, Baojin Zhu⁴, Carol L Gaich⁴, Xiang Zhang⁴, Douglas E. Schlichting⁴, Christina L. Dickson⁴ and Tsutomu Takeuchi⁵, ¹NDORMS, University of Oxford, Oxford, United Kingdom, ²University of Texas Southwestern Medical Center, Dallas, TX, ³Rheumatology, Rheumatology Care Center, Birmingham, AL, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Assessment of pain improvement during treatment for rheumatoid arthritis (RA) may help frame patient expectations and may be useful to clinical decision-making and discussions…
Abstract Number: 856 • 2017 ACR/ARHP Annual Meeting
Trends and Predictors of Chronic Opioid Use in Individuals with RA
Yvonne C. Lee¹, Joel Kremer², Hongshu Guan³, Jeffrey D Greenberg⁴ and Daniel H. Solomon⁵, ¹Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²The Center for Rheumatology, Albany Medical College, Albany, NY, ³Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴NYU School of Medicine, New York, NY, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: The opioid epidemic is a major public health concern, requiring urgent action. However, little is known about chronic opioid use among individuals with RA.…
Abstract Number: 858 • 2017 ACR/ARHP Annual Meeting
Identification of Clinically Relevant Pain Profiles in Individuals with Active RA
Alyssa Wohlfahrt¹, Zhi Zhang¹, Bing Lu², Clifton O. Bingham III³, Marcy B. Bolster⁴, Wendy Marder⁵, Larry W. Moreland⁶, Kristine Phillips⁷, Tuhina Neogi⁸ and Yvonne C. Lee⁹, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Internal Medicine-Rheumatology, University of Michigan, Ann Arbor, MI, ⁶Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Rheumatology, Vanderbilt University Medical Center, Nashville, TN, ⁸Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁹Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Despite DMARD treatment, many RA patients continue to suffer from pain. Defining distinct pain phenotypes may advance the use of therapies targeted at specific…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].